Skip to main content
Claude Eric Bulabois on Muck Rack

Claude Eric Bulabois

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Claude Eric

Contact Claude Eric, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study

|
By Jan Styczynski, Gloria Tridello, Inge Verheggen, Nina Knelange, Lotus Wendel, Per Ljungman, José Luis Piñana, Malgorzata Mikulska, Lidia Gil, Simone Cesaro, Fabio Ciceri, Raffaella Greco, Depei Wu, Didier Blaise, Raffaella Cerretti, Patrice Chevallier, Edouard Forcade, Flore Sicre de Fontbrune, Mohamad Mohty Verified, Claude Eric Bulabois, Stéphanie Nguyen Quoc, Ibrahim Yakoub-Agha, Rafael de la Camara, Dina Averbuch, Sophie Ducastelle Lepretre
| Nature Verified
Allogeneic hematopoietic cell transplantation (allo-HCT), including haploidentical HCT (haplo-HCT) is a potentially curative therapy that shows encouraging long-term outcomes in hematological diseases [1,2,3,4]. In prior studies and meta-analyses, donor and recipient Epstein-Barr virus (EBV) seropositivity has been shown to significantly impact transplant outcomes after allo-HCT [5,6,7,8].
Open in Who Shared Issue with article?
See all 1 articles